Skip to content
GLP-1 Decoder

GLP-1 Plateau: Why Weight Loss Stalls

Results vary a lot by dose and by person. In SURMOUNT-1, the average loss ran from 15% on tirzepatide 5 mg weekly to 20.9% on tirzepatide 15 mg weekly, against 3.1% on placebo.

Average loss, top dose
20.9%
On placebo
3.1%
Trial length
72 weeks
Trial
SURMOUNT-1

Weight loss and half-life overview

How long each medicine remains in your body
Wegovy7 dOzempic7 dRybelsus7 dZepbound5.5 dMounjaro5 dTrulicity5 dFoundayo1.6 dSaxenda0.5 dVictoza0.5 dByetta0.1 d

Measured in days, half-life tells you how long your body takes to clear half a dose. The figure comes from section 12.3 in every FDA label.

Weight lost in the main weight trial for each medicine
Zepbound20.9%Wegovy14.9%Foundayo11.1%Saxenda7.4%

Body weight percentage. The trials differed in their doses and lengths, so compare each result with its own placebo on the relevant page.

Sources (10)

FDA label (DailyMed) 1 2 3 4 5 6 7 8 9 10.

GLP-1 plateau: the numbers first

Each GLP-1 appears at its highest dose in the main weight trial. Different trials enrolled different people.

Average weight loss in each trial, grouped by dose
TrialDose groupAverage weight lostPlacebo or comparisonWeeksWho was in it
STEP 1Semaglutide 2.4 mg weekly14.9%2.4%68Adults with obesity or overweight, without diabetes
OASIS 4Wegovy pill 25 mg daily13.6%2.4%64Adults with obesity or overweight, without diabetes
SURMOUNT-1Tirzepatide 15 mg weekly20.9%3.1%72Adults with obesity or overweight, without diabetes
SURMOUNT-2Tirzepatide 15 mg weekly14.7%3.2%72Adults with obesity or overweight and type 2 diabetes
SCALE Obesity and PrediabetesLiraglutide 3.0 mg daily7.4%3%56Adults with obesity or overweight but no type 2 diabetes
ATTAIN-1Foundayo 17.2 mg daily11.1%2.1%72Adults with obesity or overweight, without diabetes
ATTAIN-2Foundayo 17.2 mg daily9.6%2.5%72Adults with obesity or overweight and type 2 diabetes
STEP 2Semaglutide 2.4 mg weekly9.6%3.4%68Adults with obesity or overweight and type 2 diabetes

Sources: STEP 1 (FDA label (DailyMed)), SURMOUNT-1 (FDA label (DailyMed)), SURMOUNT-2 (PubMed), SCALE Obesity and Prediabetes (FDA label (DailyMed)), ATTAIN-1 (FDA label (DailyMed)), STEP 2 (PubMed)

What causes the stall, and what helps

  1. Check which step of the dose you are on. In every trial above, people taking lower doses lost less weight.
  2. Over the past month, count doses you missed and doses you took late
  3. Note what you eat and drink for a few days. Liquid calories and grazing add up as your portions get smaller.
  4. Eat protein at every meal and continue strength exercise. This way, most of what you lose is fat.
  5. Look at your sleep and stress, because both affect appetite.
  6. Ask your pharmacist whether any other medicines you take can cause weight gain.
  7. If your progress has stalled for months, ask your prescriber about switching medicines and about a thyroid or blood sugar check.